Khiron Life Sciences Celebrates Big Growth in Colombia and Expands into New Latin American and European Markets
According to New Frontier Data
Akebia Therapeutics Posts Study Titled ‘Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (IMPACT)’ To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04922645
Why Ocugen Shares Are Getting Hammered Today
Ocugen Inc (NASDAQ: OCGN) shares were trading 22.18% lower off the open Thursday at $7.24 after the company announced it will pursue a biologics license application path for its COVID-19 vaccine instead of emergency use authorization.
Seres Therapeutics Presents Research From Early-Stage Microbiome Therapeutic Oncology Programs At ASCO 2021 Meeting
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Köln, Germany) demonstrating that decreased
Gilead Says Co’s Kite’s Tecartus Demonstrates ‘High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation’
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
-- 71% of Adult Patients in Phase 2 ZUMA-3
Tandem Diabetes Care Announces Presentations Demonstrating ‘Immediate And Sustained Real-World Improvements With Control-IQ Technology’
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, announced data presented this week on real-world use of the t:slim X2™ insulin pump with Control-IQ™
ADC Therapeutics Presents Updated Clinical Data At 2021 ASCO Meeting
ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated
Incyte, MorphoSys Announce 3-Year Results From Phase 2 L-MIND Study Of Tafasitamab In Combination With Lenalidomide For Treatment Of Relapsed Or Refractory DLBCL
-- Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Incyte (NASDAQ:INCY) and MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG ((FSE:
Chimerix Shares Spike Higher; FDA Approves Co’s Tembexa To Treat Smallpox
https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-treat-smallpox